Currently, pitavastatin (PIT) and atorvastatin (ATO) are widely used statins in daily practice of hypercholesterolemia treatment because of their effectiveness in lowering serum low-density lipoprotein cholesterol (LDL-C)\(^1\), \(^2\). Numerous pieces of evidence have demonstrated that they are highly effective in preventing the development of atherosclerotic cardiovascular disease (ASCVD)\(^3\)-\(^5\). It remains to be clarified whether there are any differences in the degree for ASCVD prevention by PIT and ATO.

Lipoprotein lipase (LPL) is a lipolytic enzyme involved in catalyzing the hydrolysis of triglycerides (TG) in chylomicrons and very low-density lipoprotein (VLDL) particles.

Over the last few decades, increasing attention has been paid to the clinical significance of measuring serum LPL protein mass. Several clinical studies have shown that increased LPL mass is inversely associated with the development of atherosclerosis\(^6\)-\(^8\). Several researchers have paid attention to the effect of statin treatment on changes in serum LPL mass\(^9\), \(^10\) or post-heparin plasma LPL activity\(^11\) (Table 1).

Among them, several studies have shown that ATO treatment is associated with no changes\(^9\) or increases\(^10\) in serum LPL mass or post-heparin plasma LPL activity\(^11\), whereas PIT treatment is associated with increased LPL mass. Interestingly, Kakuda et al.\(^12\) have shown by directly switching from ATO (10 mg/day) to PIT (2 mg/day) treatment that PIT was more effective than ATO in increasing LPL mass.

In the current issue of Journal of Atherosclerosis and Thrombosis, Nagayama et al.\(^13\) have reported that PIT reduced CV events more efficaciously than ATO despite their similar LDL cholesterol-lowering effects and suggested that increased LPL mass during the first year after PIT treatment is associated with this efficacy.

What would be the mechanisms through which PIT treatment is associated with increased LPL mass? Unlike fibrates, statins are not a ligand of peroxisome proliferator-activated receptor \(\alpha\) (PPAR\(\alpha\)); however, a study using rat hepatoma McARH7777 cells showed that PIT increased PPAR\(\alpha\) mRNA and its downstream gene expression\(^14\).

Another potential mechanism underlying increasing serum LPL owing to PIT could be explained by its insulin sensitizing effect. Serum LPL mass has been shown to be a useful parameter for predicting insulin sensitivity\(^15\). Indeed some study\(^1\) on Japanese hyperlipidemic subjects have shown that 1 mg/day of PIT decreased the HOMA-IR by 13% (\(p \lt 0.001\)), which was in stark contrast with ATO being associated with increasing this parameter by \(+26\%)\).

Next, what would be the mechanisms for the correlation of increased serum LPL with decreased cardiovascular disease? Unlike post-heparin plasma LPL, serum LPL per se does not appear to be catalytically active and thus, its concentration could be a marker for the amount of systemically available (catalytically) active LPL. Serum LPL mass may, however, also have a direct atheroprotective role in mediating the clearance of atherogenic lipoproteins remnants\(^16\), independent of its catalytic activity. The Epic-Norfolk prospective study\(^6\), which is mentioned earlier, showed that the observed significantly inversely relation of LPL mass with the incidence of cardiovascular disease disappeared when triglyceride values were adjusted. This indicates that increased LPL mass may contribute to reductions in the incidence of cardiovascular disease by somehow decreasing triglyceride values.

Besides LPL mass, there has been an interesting...
study comparing the effect of ATO and PIT on serum lipids\(^7\). They reported that serum high-density lipoprotein cholesterol (HDL-C) levels increased after 1, 3, and 6 months of PIT, whereas it was decreased even after 6 months of ATO, suggesting that PIT is superior to ATO in changes in serum HDL-C levels. This finding is in line with the report in clinical practice that PIT was associated with an increase in serum HDL-C level\(^2\).

In conclusion, PIT may have additional favorable effects on serum lipid and lipolytic enzyme levels compared with ATO, leading to further antiatherogenic effects.

**Conflicts of Interest**

None.

**References**

1. Nakagomi A, Shibui T, Kohashi K, Kosugi M, Kusama Y, Atarashi H, Shimizu W. Differential Effects of Atorvastatin and Pitavastatin on Inflammation, Insulin Resistance, and the Carotid Intima-Media Thickness in Patients with Dyslipidemia. J Atheroscler Thromb, 2015; 22: 1158-1171

2. Teramoto T. Pitavastatin: clinical effects from the LIVES Study. Atheroscler Suppl, 2011; 12 : 285-288

3. Schwartz GG, Olsson AG, Ezekowitz MD, Ganz R, Oliver MF, Waters D, Zeiher A, Chaitman BR, Leslie S, Stern T; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA, 2001; 285: 1711-1718

4. Murphy SA, Cannon CP, Wiviott SD, McCabe CH, Braunwald E. Reduction in recurrent cardiovascular events with intensive lipid-lowering statin therapy compared with moderate lipid-lowering statin therapy after acute coronary syndromes from the PROVE IT-TIMI 22 (Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis In Myocardial Infarction 22) trial. J Am Coll Cardiol, 2009; 54: 2358-2362

5. Taguchi I, Iimuro S, Iwata H, Takashima H, Abe M, Amiya E, Ogawa T, Ozaki Y, Sakuma I, Nakagawa Y, Hibi K, Hiro T, Fukumoto Y, Hokimoto S, Miyauchi K, Yamazaki T, Ito H, Otsui Y, Kimura K, Takekoshi J, Hiyama A, Yokoi H, Kitagawa K, Urabe T, Okada Y, Terayama Y, Toyoda K, Nagao T, Matsumoto M, Ohashi Y, Kaneko T, Fujita R, Ohtsu H, Ogawa H, Daida H, Shimokawa H, Saito Y, Kimura T, Inoue T, Matsuzaki M, Nagai R. High-Dose Versus Low-Dose Pitavastatin in Japanese Patients With Stable Coronary Artery Disease (REAL-CAD): A Randomized Superiority Trial. Circulation, 2018; 137: 1997-2009

6. Rip J, Nierman MC, Warche M, Lüben R, Bingham SA, Day NE, van Mier JN, Hitman BA, Kastell E, Kuivenhoven JA, Khaw KT, Boekholdt SM. Serum lipoprotein lipase concentration and risk for future coronary artery disease: the EPIC-Norfolk prospective population study. Arterioscler Thromb Vasc Biol, 2006; 26: 637-642

7. Kobayashi J, Mabuchi H. Lipoprotein lipase and atherosclerosis. Ann Clin Biochem, 2015; 52: 632-637

8. Hiisumoto T, Ohsawa H, Uchi T, Noike H, Kanai M, Yoshimura M, Miyashita Y, Watanabe H, Shirai K. Preheparin serum lipoprotein lipase mass is negatively related to coronary atherosclerosis. Atherosclerosis, 2000; 153: 391-396

9. Kobayashi J, Maruyama T, Masuda M, Shinomiya M. Effect of atorvastatin treatment on lipoprotein lipase mass in the pre-heparin plasma in Japanese hyperlipidemic subjects. Clin Chim Acta, 2001; 314: 261-264

10. Endo K, Miyashita Y, Saiki A, Oyama T, Koide N, Ozaki H, Otsuka M, Ito Y, Shirai K. Atorvastatin and pravastatin elevated pre-heparin lipoprotein lipase mass of type 2 diabetes with hypercholesterolemia. J Atheroscler Thromb, 2004; 11: 341-347

11. Kakuda H, Matoba M, Nakatoh H, Nagao T, Takekoshi N. Comparison of atorvastatin, pitavastatin and rosuvastatin for residual cardiovascular risk using non-fasting blood sampling. Scand J Clin Lab Invest, 2014; 74: 285-295

12. Nagayama D, Saiki A, Watanabe Y, Yamaguchi T, Ohira M, Sato N, Kanayama M, Moroi M, Miyashita Y, Shirai K, Tatsuno I. Prevention of cardiovascular events with pitavastatin is associated with increased serum lipoprotein lipase mass level: subgroup analysis of the TOHO-LIP J Atheroscler Thromb, 2021; in press. doi: https://doi.org/10.5551/jat.62141

---

**Table 1. Clinical studies on the effects of pitavastatin or atorvastatin on serum lipoprotein lipase**

| Authors          | year | Subjects                          | Statin     | Serum LPL      |
|------------------|------|-----------------------------------|------------|---------------|
| Kobayashi et al. | 2001 | Hyperlipidemia (n = 21)           | ATO (10 mg/day) | No change |
| Endo et al.      | 2004 | Type 2 diabetes (n = 24)          | ATO (10 mg/day) | increased * |
| Schneider et al. | 2004 | Type 2 diabetes (n = 61)          | ATO (40 mg/day) | increased * |
| Kakuda et al.    | 2014 | Dyslipidemia (n = 129)            | PIT (2 mg/day)   | increased   |
| Nagayama et al.  | 2021 | hypercholesterolemia (n = 107)    | PIT (2 mg/day)   | increased   |
|                  |      | hypercholesterolemia (n = 116)    | ATO (10 mg/day) | No change  |

LPL, lipoprotein lipase; ATO, atorvastatin; PIT, pitavastatin

*lipoprotein lipase activity in post-heparin plasma
13) Schneider JG, Eynatten MV, Dugi KA. Atorvastatin increases lipoprotein lipase expression in vitro and activity in vivo. J Atheroscler Thromb, 2005; 12: 232-233
14) Maejima T, Sugano T, Yamazaki H, Yoshinaka Y, Doi T, Tanabe S, Nishimaki-Mogami T. Pitavastatin increases ABCA1 expression by dual mechanisms: SREBP2-driven transcriptional activation and PPARα-dependent protein stabilization but without activating LXR in rat hepatoma McARH7777 cells. J Pharmacol Sci, 2011; 116: 107-115
15) Hanyu O, Miida T, Obayashi K, Ikarashi T, Soda S, Kaneko S, Hirayama S, Suzuki Nakamura Y, Yamatani K, Aizawa Y. Lipoprotein lipase (LPL) mass in preheparin serum reflects insulin sensitivity. Atherosclerosis, 2004; 174: 385-390
16) Beisiegel U, Weber W, Bengtsson-Olivecrona G. Lipoprotein lipase enhances the binding of chylomicrons to low density lipoprotein receptor related protein. Proc Natl Acad Sci U S A, 1991; 88: 8342-8346
17) Shimabukuro M, Higa M, Tanaka H, Shimabukuro T, Yamakawa K, Masuzaki H. Distinct effects of pitavastatin and atorvastatin on lipoprotein subclasses in patients with Type 2 diabetes mellitus. Diabet Med, 2011; 28: 856-864